Press releases
02 November 2022 | 02:05 PM
Dr Michael Lichtenberg today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22
HORSHAM, UK – 01 Nov 2022 – Veryan Medical Ltd announces that Dr Michael Lichtenberg (Klinikum Hochsauerland, Arnsberg, Germany) today presented 36-Month Outcomes for the BioMimics 3D® Stent in Longer Lesions: A Subgroup Analysis of the MIMICS-3D EU Registry at VIVA 22 in the Late Breaking Clinical Trials session at VIVA 2022 in Las Vegas, US.
07 October 2022 | 10:21 AM
BioMimics 3D® Vascular Stent System granted Good Design Award 2022
TOKYO, JAPAN – 07 OCTOBER 2022 – Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”, subsidiary of Otsuka Holdings Co., Ltd.) is pleased to announce that the BioMimics 3D Vascular Stent System has been granted a Good Design Award 2022 from the Japan Institute of Design Promotion.
01 May 2022 | 01:03 PM
BioMimics 3D®, a next generation biomimetic peripheral stent, now available nationwide with Veryan Medical and Premier collaboration
HORSHAM, UK – 01 MAY 2022 – Veryan Medical Inc. has been awarded a group purchasing agreement for Peripheral and Biliary Stents with Premier, Inc. Effective 01 May 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BioMimics 3D Vascular Stent System.
Latest News
Board Announcement – Appointment of new CEO
HORSHAM, UK – 01 SEPTEMBER 2022 – The Board of Veryan Holdings Ltd announces that, following 11 years of service, including 8 years as COO and 3 years as CEO, Nick Yeo has decided to leave Veryan to pursue new professional and personal goals.
BioMimics 3D US launch
Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly-differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up.
